Table 2 Demographics
P1 | P2A (DL0–DL4) | P2B (DL0–DL3) | Total P2A+P2B | |
|---|---|---|---|---|
Number of patients | 9 | 33 | 25 | 58 |
Gender, n (%) | ||||
Male | 4 (44%) | 14 (42%) | 11 (44%) | 37 (64%) |
Female | 5 (56%) | 19 (57%) | 14 (56%) | 21 (36%) |
Age, mean (range) | 59 (37–78) | 50.4 (18–69) | 49.9 (32–72) | 52.3 (18–72) |
ECOG performance status, n (%) | ||||
0 | 5 (56%) | 19 (57%) | 8 (32%) | 27 (47%) |
1 | 4 (44%) | 14 (42%) | 17 (68%) | 31 (53%) |
Primary site of disease, n (%) | 0 | |||
Ovary | 0 | 10 (30%) | 6 (24%) | 16 (28%) |
Pancreas | 1 (11%) | 2 (6%) | 5 (20%) | 7 (12%) |
Sarcoma (STS) | 1 (11%) | 2 (6%) | 3 (12%) | 4 (7%) |
Colon/rectum | 2 (22%) | 2 (6%) | 3 (12%) | 4 (7%) |
Breast | 1 (11%) | 2 (6%) | 0 | 2 (3%) |
Oesophagus | 0 | 1 (3%) | 1 (4%) | 2 (3%) |
Gastric | 0 | 2 (6%) | 0 | 2 (3%) |
NSCLC | 1 (11%) | 0 | 1 (4%) | 1 (2%) |
Endometrium or uterus | 1 (11%) | 1 (3%) | 1 (4%) | 1 (2%) |
Cervix | 0 | 0 | 1 (4%) | 1 (2%) |
Ampulla | 0 | 1 (3%) | 0 | 1 (2%) |
Peritoneal | 0 | 1 (3%) | 0 | 1 (2%) |
Bladder | 0 | 1 (3%) | 0 | 1 (2%) |
Kidney | 0 | 1 (3%) | 0 | 1 (2%) |
Neuroendocrine | 0 | 0 | 1 (4%) | 1 (2%) |
Vulva | 0 | 1 (3%) | 0 | 1 (2%) |
Bone | 0 | 1 (3%) | 0 | 1 (2%) |
GIST | 0 | 2 (6%) | 0 | 2 (3%) |
Leiomyosarcoma | 0 | 3 | 1 (4%) | 4 (7%) |
Angiosarcoma | 0 | 1 (4%) | 1 (2%) | |
Osteosarcoma | 0 | 2 (6%) | 0 | 2 (3%) |
Synovial sarcoma | 1 (11%) | 1 (3%) | 0 | 1 (2%) |
Epitheloid hemangio-epithelioma | 0 | 0 | 1 (4%) | 1 (2%) |
Melanoma choroidea | 0 | 1 (3%) | 0 | 1 (2%) |
Renal cell | 1 (11%) | 0 | ||
Duration of disease, days (median (range)) | 788 (147–4307) | 1000 (151–4415) | 540 (33–4192) | 718 (70–4415) |
Prior therapies, n (%) | ||||
Any therapy | 9 (100%) | 33 (100%) | 24 (96%) | 57 (98%) |
Immunotherapy | 0 | 30 (90%) | 22 (88%) | 52 (90%) |
Chemotherapy 1 line | 1 (11%) | 8 (24%) | 1 (4%) | 10 (17%) |
Chemotherapy 2 lines | 3 (33%) | 4 (12%) | 3 (12%) | 7 (12%) |
Chemotherapy 3 lines | 1 (11%) | 5 (15%) | 8 (32%) | 13 (22%) |
Chemotherapy 4 lines | 3 (33%) | 5 (15%) | 7 (28%) | 12 (21%) |
Chemotherapy 5 and + lines | 1 (11%) | 8 (24%) | 2 (%) | 10 (17%) |
Hormonal therapy | 2 (22%) | 1 (3%) | 1 (4%) | 2 (3%) |
Biologic therapy | 3 (33%) | 7 (21%) | 5 (20%) | 12 (21%) |
Surgery | 8 (89%) | 30 (90%) | 19 (76%) | 49 (84%) |
Radiotherapy | 3 (33%) | 12 (36%) | 12 (48%) | 24 (41%) |
Unknown | 1 (11%) | 2 (6%) | 1 (4%) | 3 (5%) |
